Management of treatment-emergent peripheral neuropathy in multiple myeloma. (Q37970946)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Management of treatment-emergent peripheral neuropathy in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

peripheral neuropathy

1 reference

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S. Vincent Rajkumar

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Herve Avet-Loiseau

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Michele Cavo

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Athanasios Dimopoulos

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Glyn R Morgan

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

36

B G M Durie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

P G Richardson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Delforge

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Beksac

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

P Wen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J L Jongen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

O Sezer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

E Terpos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

N Munshi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Palumbo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J L Harousseau

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

P Moreau

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J H Lee

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

P Voorhees

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

W J Chng

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Mazumder

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S Usmani

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

H Einsele

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R Comenzo

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R Orlowski

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

D Vesole

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J J Lahuerta

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R Niesvizky

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

D Siegel

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M-V Mateos

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S Lonial

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S Jagannath

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J Bladé

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J San Miguel

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

K C Anderson

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

P Sonneveld

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

23 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

595-608

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.346

19 January 2020

exact match

0 references

cites work

Neurological aspects of multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Neuropathies associated with paraproteinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Thalidomide-induced neuropathy: a ganglionopathy?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Thalidomide-induced neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Evidence for direct axonal toxicity in vincristine neuropathy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

The troublesome toxicity of peripheral neuropathy with thalidomide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Sequence variation at multiple loci influences red cell hemoglobin concentration

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Genetic variation associated with bortezomib-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Thalidomide for treatment of multiple myeloma: 10 years later

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Balancing act for elderly myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.346

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.346

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22193964%20AND%20SRC:MED&resulttype=core&format=json

release_u3jazedhfbbtllwctlqwqfmwwu

19 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u3jazedhfbbtllwctlqwqfmwwu

24 November 2022

mapped directly with Wikidata item

1 reference